ATE214066T1 - Substituierte 1,3-oxathiolane mit antiviralen eigenschaften - Google Patents

Substituierte 1,3-oxathiolane mit antiviralen eigenschaften

Info

Publication number
ATE214066T1
ATE214066T1 AT95915098T AT95915098T ATE214066T1 AT E214066 T1 ATE214066 T1 AT E214066T1 AT 95915098 T AT95915098 T AT 95915098T AT 95915098 T AT95915098 T AT 95915098T AT E214066 T1 ATE214066 T1 AT E214066T1
Authority
AT
Austria
Prior art keywords
oxathiolanes
substituted
antiviral properties
relates
fluorocytosine
Prior art date
Application number
AT95915098T
Other languages
English (en)
Inventor
Tarek S Mansour
Haolun Jin
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Application granted granted Critical
Publication of ATE214066T1 publication Critical patent/ATE214066T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95915098T 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antiviralen eigenschaften ATE214066T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/230,317 US5587480A (en) 1990-11-13 1994-04-20 Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
PCT/CA1995/000212 WO1995029176A1 (en) 1994-04-20 1995-04-19 Substituted 1,3-oxathiolanes with antiviral properties

Publications (1)

Publication Number Publication Date
ATE214066T1 true ATE214066T1 (de) 2002-03-15

Family

ID=22864746

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04018075T ATE360019T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antviralen eigenschaften
AT01118810T ATE275144T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
AT95915098T ATE214066T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antiviralen eigenschaften

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT04018075T ATE360019T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antviralen eigenschaften
AT01118810T ATE275144T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antiviralen eigenschaften

Country Status (12)

Country Link
US (1) US5587480A (de)
EP (3) EP1473294B1 (de)
JP (1) JPH09512526A (de)
AT (3) ATE360019T1 (de)
AU (1) AU693884B2 (de)
CA (1) CA2188283C (de)
DE (3) DE69533458T2 (de)
DK (3) DK0756595T3 (de)
ES (3) ES2228714T3 (de)
HK (1) HK1041487B (de)
PT (3) PT1473294E (de)
WO (1) WO1995029176A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
TW536403B (en) 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
CA2340214C (en) 1998-08-12 2007-10-30 Triangle Pharmaceuticals, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
BR0104461A (pt) * 2000-02-10 2002-08-06 Mitsui Chemicals Inc Processo seletivo para produzir um anÈmero a partir de um derivado de sacarìdeo 1-fosforilado e processo para produzir um nucleosìdeo
WO2002051852A1 (fr) * 2000-12-27 2002-07-04 Mitsui Chemicals, Inc. Procede de production d'un derive de saccharide non naturel
EP1406896B8 (de) * 2001-06-15 2006-11-15 Shire Biochem Inc. Stereoselektives verfahren zur herstellung von nukleosidanaloga
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
US7501514B1 (en) 2003-10-15 2009-03-10 Shire Biochem, Inc. Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides
US7968703B2 (en) * 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
AU2005329355B8 (en) * 2005-03-14 2012-02-23 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-Hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts
RU2430919C2 (ru) * 2005-03-14 2011-10-10 Шайр Канада Инк. Способы получения оптически активного цис-2-гидроксиметил-4-(цитозин-1'-ил)-1,3-оксатиолана или его фармацевтически приемлемых солей
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2008118879A2 (en) * 2007-03-23 2008-10-02 Ardea Biosciences, Inc. Antiviral compositions comprising 2 compounds
ES2542154T3 (es) * 2007-09-28 2015-07-31 Avexa Limited Un procedimiento para la resolución quiral de 1,3-oxatiolanos sustituidos en posición 2 y sustituidos en posición 4
MX2011002507A (es) * 2008-09-05 2011-07-29 Shire Canada Inc Resolucion enantiomerica de nucleosidos 1,3-oxatiolano 2,4-disustituidos.
US8153416B2 (en) 2008-12-10 2012-04-10 Thesis Chemistry, Llc Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes using enzymatic resolution
US8431699B2 (en) 2009-02-27 2013-04-30 Vertichem Corporation Method for manufacture of 2-oxoimidazolidines
TW201131192A (en) * 2010-03-01 2011-09-16 Univ Nat Central A co-crystal compound of optical devices
WO2013071353A1 (en) * 2011-11-18 2013-05-23 Avexa Limited Apricitabine and pi combination therapy
JP2012136526A (ja) * 2012-02-09 2012-07-19 Shire Canada Inc 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法
WO2024016639A1 (zh) * 2022-07-21 2024-01-25 华创合成制药股份有限公司 一种抗病毒感染的化合物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE3529263A1 (de) * 1985-08-16 1987-02-19 Hoechst Ag Verfahren zur herstellung von 2-oxo-1,3-dioxolanen
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE3827134A1 (de) * 1988-08-10 1990-03-15 Bayer Ag Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
JP2960164B2 (ja) * 1990-11-13 1999-10-06 バイオケム ファーマ インコーポレイテッド 抗ウイルス特性を有する置換１，３−オキサチオラン類および置換１，３−ジチオラン類
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides

Also Published As

Publication number Publication date
PT1473294E (pt) 2007-06-11
PT1153924E (pt) 2005-01-31
CA2188283A1 (en) 1995-11-02
DE69525742T2 (de) 2002-09-26
DK1473294T3 (da) 2007-09-17
EP1473294B1 (de) 2007-04-18
ES2286542T3 (es) 2007-12-01
EP0756595A1 (de) 1997-02-05
EP1153924A3 (de) 2001-11-21
DK1224940T3 (da) 2004-12-27
EP1153924B1 (de) 2004-09-01
AU2211895A (en) 1995-11-16
HK1005544A1 (en) 1999-01-15
EP1473294A2 (de) 2004-11-03
ES2228714T3 (es) 2005-04-16
DE69535476D1 (de) 2007-05-31
DE69533458T2 (de) 2005-10-27
CA2188283C (en) 2003-11-04
JPH09512526A (ja) 1997-12-16
EP1473294A3 (de) 2004-11-17
DE69533458D1 (de) 2004-10-07
EP0756595B1 (de) 2002-03-06
US5587480A (en) 1996-12-24
HK1041487B (en) 2005-01-07
EP1153924A2 (de) 2001-11-14
AU693884B2 (en) 1998-07-09
ATE275144T1 (de) 2004-09-15
DE69525742D1 (de) 2002-04-11
ATE360019T1 (de) 2007-05-15
DK1224940T4 (da) 2010-10-25
PT756595E (pt) 2002-08-30
WO1995029176A1 (en) 1995-11-02
HK1073460A1 (en) 2005-10-07
HK1041487A1 (en) 2002-07-12
ES2172580T3 (es) 2002-10-01
DE69535476T2 (de) 2008-01-03
DK0756595T3 (da) 2002-06-17

Similar Documents

Publication Publication Date Title
DE69533458D1 (de) Substituierte 1,3-Oxathiolane mit antiviralen Eigenschaften
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
SE9604786D0 (sv) New compounds
MD950086A (ro) Utilizare a analogilor nucleozidici ai 1,3-oxatiolanei in tratamentul hepatitei B Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis B
DE69131311D1 (de) Fibrinogen-Rezeptor-Antagonisten
DK274788A (da) Tetrazoler
PH25571A (en) Alpha'-alkyl-4-amino-3-quinolinemethanols, 1-(4-aralkylamino-3-quinolinyl) alaknones, their use as medicaments
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
ATE147071T1 (de) 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung
DK0658110T3 (da) Anvendelse af norastemizol til behandling af allergisk rhinitis
DK0573218T3 (da) 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse
PT992509E (pt) Novos derivados macrolidos
GR3036532T3 (en) Use of lactam compounds as pharmaceutical agents
ES552578A0 (es) Procedimiento para preparar 5h,11h-pirrolo (2,1-c)(1,4)benzoxazepinas sustituidas en posicion 11
ES2102772T3 (es) Compuesto citotoxico y antiviral.
ATE58135T1 (de) 1,3-oxathianderivate.
NZ229300A (en) Substituted-2-ethenyl-3,4,5,6-tetrahydrothieno (4,3,2-cf)(3)benzazepine derivatives and pharmaceutical compositions
EP0802179A4 (de) Derivate substituierter amidinonaphthylester
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
FI905922A0 (fi) Antagonister foer a-adrenerga receptorer.
IT1262952B (it) Tetraalchilpiperidine, loro preparazione e loro impiego come stabilizzanti alla luce. (caso 153-5502)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name